{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:25:30Z","timestamp":1789424730879,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00360-w","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T10:04:24Z","timestamp":1653905064000},"page":"1167-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices"],"prefix":"10.1007","volume":"11","author":[{"given":"Ilse S.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Mazzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa T.","family":"Belter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e1ngel E.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"360_CR1","doi-asserted-by":"publisher","unstructured":"Gregg A, Getz N, Benger J, Anderson A. A novel collaborative approach to building better clinical trials: new insights from a patient engagement workshop to propel patient-centricity forward. Ther Innov Regul Sci. 2019. https:\/\/doi.org\/10.1177\/2168479019849875.","DOI":"10.1177\/2168479019849875"},{"issue":"11","key":"360_CR2","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.clinthera.2017.09.010","volume":"39","author":"MJ Lamberti","year":"2017","unstructured":"Lamberti MJ, Awatin J. Mapping the landscape of patient-centric activities within clinical research. Clin Ther. 2017;39(11):2196\u2013202. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.010.","journal-title":"Clin Ther"},{"issue":"3","key":"360_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4103\/2229-3485.159936","volume":"6","author":"NS Sharma","year":"2015","unstructured":"Sharma NS. Patient centric approach for clinical trials: current trend and new opportunities. Perspect Clin Res. 2015;6(3):134\u20138. https:\/\/doi.org\/10.4103\/2229-3485.159936.","journal-title":"Perspect Clin Res"},{"key":"360_CR4","doi-asserted-by":"publisher","unstructured":"TransCelerate Biopharma Toolkits Core Team, Elmer M, Florek C, et al. Amplifying the voice of the patient in clinical research: development of toolkits for use in designing and conducting patient-centered clinical studies. Ther Innov Regul Sci. 2020;54(6):1489\u20131500. https:\/\/doi.org\/10.1007\/s43441-020-00176-6.","DOI":"10.1007\/s43441-020-00176-6"},{"key":"360_CR5","doi-asserted-by":"publisher","unstructured":"Chappuy H, Doz F, Blanche S, Gentet JC, Pons G, Tr\u00e9luyer JM. Parental consent in paediatric clinical research.\u00a0Arch Dis Child. 2006;91(2):112\u2013116. https:\/\/doi.org\/10.1136\/adc.2005.076141.","DOI":"10.1136\/adc.2005.076141"},{"issue":"4","key":"360_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"issue":"18","key":"360_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"issue":"1","key":"360_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"issue":"1","key":"360_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"key":"360_CR10","doi-asserted-by":"publisher","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157\u201367. https:\/\/doi.org\/10.1002\/mus.24497.","DOI":"10.1002\/mus.24497"},{"key":"360_CR11","doi-asserted-by":"publisher","unstructured":"Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:1. https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5.","DOI":"10.1016\/s0022-510x(96)00284-5"},{"issue":"5","key":"360_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1086\/302369","volume":"64","author":"B Wirth","year":"1999","unstructured":"Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999;64(5):1340\u201356. https:\/\/doi.org\/10.1086\/302369.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"360_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119(4):422\u20138. https:\/\/doi.org\/10.1007\/s00439-006-0156-7.","journal-title":"Hum Genet"},{"issue":"1","key":"360_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313. https:\/\/doi.org\/10.3233\/JND-190424.","journal-title":"J Neuromuscul Dis"},{"key":"360_CR15","unstructured":"Cure SMA. Best practices for clinical research coordinators in spinal muscular atrophy (SMA). Elk Grove Village (IL): Cure SMA. 2019. https:\/\/www.curesma.org\/clinical-trial-readiness\/."},{"key":"360_CR16","unstructured":"Cure SMA. Cure SMA clinical trial readiness toolkit. Elk Grove Village (IL): Cure SMA. 2018. https:\/\/www.curesma.org\/clinical-trial-readiness\/. Accessed Feb 2022."},{"key":"360_CR17","unstructured":"Cure SMA. Clinical trial readiness. 2020. https:\/\/www.curesma.org\/clinical-trial-readiness\/."},{"key":"360_CR18","unstructured":"Cure SMA. Voice of the Patient Report. 2018. https:\/\/curesma.wpengine.com\/wp-content\/uploads\/2018\/01\/SMA-VoP-for-publication-1-22-2018.pdf. Accessed Feb 2022."},{"key":"360_CR19","unstructured":"U.S. Food and Drug Administration (FDA). News release: FDA approves first drug for spinal muscular atrophy. 2016. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm. Accessed 19 Apr 2021."},{"key":"360_CR20","unstructured":"US Food and Drug Administration (FDA). News release: FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease. Accessed 19 Apr 2021."},{"key":"360_CR21","unstructured":"US Food and Drug Administration (FDA). News release: FDA approves oral treatment for spinal muscular atrophy. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy\u00a0. Accessed 19 Apr 2021."},{"key":"360_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-020-01387-8","volume":"15","author":"I Peterson","year":"2020","unstructured":"Peterson I, Cruz R, Sarr F, et al. The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet J Rare Dis. 2020;15:118. https:\/\/doi.org\/10.1186\/s13023-020-01387-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"360_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12305","volume":"79","author":"PD Joseph","year":"2015","unstructured":"Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357\u201369. https:\/\/doi.org\/10.1111\/bcp.12305.","journal-title":"Br J Clin Pharmacol"},{"key":"360_CR24","doi-asserted-by":"publisher","unstructured":"Cousino MK, Zyzanski SJ, Yamokoski AD, et al. Communicating and understanding the purpose of pediatric phase I cancer trials. J Clin Oncol. 2012;30(35):4367\u201372. https:\/\/doi.org\/10.1200\/JCO.2012.42.3004.","DOI":"10.1200\/JCO.2012.42.3004"},{"key":"360_CR25","doi-asserted-by":"publisher","unstructured":"Gainotti S, Turner C, Woods S, et al. Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. Eur J Hum Genet. 2016;24(9):1248\u201354. https:\/\/doi.org\/10.1038\/ejhg.2016.2.","DOI":"10.1038\/ejhg.2016.2"},{"key":"360_CR26","doi-asserted-by":"publisher","unstructured":"Greenberg RG, Corneli A, Bradley J, et al. Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: findings from the clinical trials transformation initiative. Contemp Clin Trials Commun. 2017;9:7\u201312. https:\/\/doi.org\/10.1016\/j.conctc.2017.11.006.","DOI":"10.1016\/j.conctc.2017.11.006"},{"issue":"5","key":"360_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrg3218","volume":"13","author":"J Kaye","year":"2012","unstructured":"Kaye J, Curren L, Anderson N, et al. From patients to partners: participant-centric initiatives in biomedical research. Nat Rev Genet. 2012;13(5):371\u20136. https:\/\/doi.org\/10.1038\/nrg3218.","journal-title":"Nat Rev Genet"},{"key":"360_CR28","doi-asserted-by":"publisher","unstructured":"Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet. 2015;23(2):141\u20136. https:\/\/doi.org\/10.1038\/ejhg.2014.71.","DOI":"10.1038\/ejhg.2014.71"},{"issue":"10","key":"360_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204886","volume":"13","author":"A Kearney","year":"2018","unstructured":"Kearney A, Rosala-Hallas A, Bacon N, et al. Reducing attrition within clinical trials: the communication of retention and withdrawal within patient information leaflets. PLoS ONE. 2018;13(10): e0204886. https:\/\/doi.org\/10.1371\/journal.pone.0204886.","journal-title":"PLoS ONE"},{"key":"360_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cct.2016.06.005","volume":"49","author":"J Lentz","year":"2016","unstructured":"Lentz J, Kennett M, Perlmutter J, Forrest A. Paving the way to a more effective informed consent process: recommendations from the Clinical Trials Transformation Initiative. Contemp Clin Trials. 2016;49:65\u20139. https:\/\/doi.org\/10.1016\/j.cct.2016.06.005.","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"360_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/adc.79.2.120","volume":"79","author":"M van Stuijvenberg","year":"1998","unstructured":"van Stuijvenberg M, Suur MH, de Vos S, et al. Informed consent, parental awareness, and reasons for participating in a randomised controlled study. Arch Dis Child. 1998;79(2):120\u20135. https:\/\/doi.org\/10.1136\/adc.79.2.120.","journal-title":"Arch Dis Child"},{"issue":"6","key":"360_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.clinthera.2016.04.001","volume":"38","author":"RM Bendixen","year":"2016","unstructured":"Bendixen RM, Morgenroth LP, Clinard KL. Engaging participants in rare disease research: a qualitative study of duchenne muscular dystrophy. Clin Ther. 2016;38(6):1474-1484.e2. https:\/\/doi.org\/10.1016\/j.clinthera.2016.04.001.","journal-title":"Clin Ther"},{"key":"360_CR33","doi-asserted-by":"publisher","unstructured":"Peay HL, Tibben A, Fisher T, Brenna E, Biesecker BB. Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne\/Becker muscular dystrophy. Clin Trials 2014;11(1):77\u201385. https:\/\/doi.org\/10.1177\/1740774513512726.","DOI":"10.1177\/1740774513512726"},{"key":"360_CR34","unstructured":"Myshko D. Patient-centric trial recruitment. PharmaVoice. 2018. https:\/\/www.pharmavoice.com\/article\/2018-02-patient-recruitment\/."},{"key":"360_CR35","doi-asserted-by":"publisher","unstructured":"Woolfall K, Shilling V, Hickey H, et al. Parents\u2019 agendas in paediatric clinical trial recruitment are different from researchers\u2019 and often remain unvoiced: a qualitative study. PLoS ONE. 2013; 8(7):e67352. https:\/\/doi.org\/10.1371\/journal.pone.0067352.","DOI":"10.1371\/journal.pone.0067352"},{"key":"360_CR36","unstructured":"Patient Centricity in Clinical Trials: Lessons Learned From Big Pharma. Clinical Leader. 2017. https:\/\/www.clinicalleader.com\/doc\/patient-centricity-in-clinical-trials-lessons-learned-from-big-pharma-0001?vm_tId=2041046&user=a702003e-6b2a-4623-847b-29ae64c71b39&utm_source=et_6212879&utm_medium=email&utm_campaign=CLNCL_12-20-2017-Top10&utm_term=a702003e-6b2a-4623-847b-29ae64c71b39&utm_content=Patient+Centricity+In+Clinical+Trials%253a+Lessons+Learned+From+Big+Pharma. Accessed Mar 2017."},{"key":"360_CR37","unstructured":"A Patient\u2019s Perspective on Clinical Trials. Patient Empowerment Network. 2015. https:\/\/powerfulpatients.org\/2015\/09\/30\/a-patients-perspective-on-clinical-trials\/. Accessed 30 Sep 2015."},{"issue":"2","key":"360_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, et al. An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376. https:\/\/doi.org\/10.3233\/JND-170292.","journal-title":"J Neuromuscul Dis"},{"key":"360_CR39","unstructured":"Cystic Fibrosis Foundation. Research Milestones. 2021. https:\/\/www.cff.org\/Research\/About-Our-Research\/Research-Milestones\/. Accessed 26 Jul 2021."},{"key":"360_CR40","unstructured":"Swanson, Jeanene. FDA grants breakthrough therapy designation to amicus\u2019 experimental therapy, AT-GAA, for Late-Onset Pompe Disease. Muscular Dystrophy Association. 2019. https:\/\/strongly.mda.org\/fda-grants-breakthrough-therapy-designation-amicus-experimental-therapy-late-onset-pompe-disease\/. Accessed 7 Jul 2021."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00360-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:01:16Z","timestamp":1659106876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00360-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00360-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}